Skip to main content

16-214-05 A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

NCT03138889

A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

Associated Conditions

Multiple Tumor Types

Principal Investigator

Sponsor

Nektar Therapeutics

The purpose of the study is to study how your immune system responds to the investigational drug called bempegaldesleukin (NKTR-214) when it is combined with the approved drug pembroliumab (KEYTRUDA) in patients with locally advanced or metastatic solid tumors.